April 16, 1999American Journal of Medical Genetics
Lipoprotein lipase mutations and Alzheimer's disease
Why the study?
Do Lipoprotein lipase (LPL) mutations affect the risk of Alzheimer's disease in European-Americans?
Population
European-Americans either clinically diagnosed or pathologically confirmed as Alzheimer's disease or normal…
Comparison
Lipoprotein lipase mutations vs Normal control subjects without Alzheimer's…
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
LPL variants were associated with altered AD risk; this Level 4 evidence leaves open a causal role pending replication.
Structured PICO
Do Lipoprotein lipase (LPL) mutations affect the risk of Alzheimer's disease in European-Americans?
P
Population
European-Americans either clinically diagnosed or pathologically confirmed as Alzheimer's disease (AD) or normal control (N) subjects
I
Intervention
Lipoprotein lipase (LPL) mutations (Ser447Ter and Asn291Ser)
C
Comparator
Normal control subjects without Alzheimer's disease
O
Outcome
Frequency of LPL mutations (Alzheimer's disease risk)
LPL mutations Ser447Ter and Asn291Ser are associated with altered risk of clinically diagnosed Alzheimer's disease, suggesting a potential role for LPL in AD causation.
Limitations
- Further studies in different populations are needed to clarify the results
- In pathologically confirmed subjects, allele frequencies for AD did not significantly differ from N for either mutation
Cite This Study
Baum et al. (1999) studied this question.